DXCM
Dexcom
$69.07
▼ 4.7%Updated Today 7:15 PM ET
▼ Down 10.5% over the last 12 months
Market Cap
$27.96B
P/E
30.34x
Forward P/E (est.)
21.67x
ROE
33.8%
Revenue Growth
16.1%
EPS Growth
77.5%
Profit Margin
19.3%
FCF Yield
1.8%
Debt / Equity
0.47x
ROIC
24.0%
Interest Coverage
44.92x
Current Ratio
1.95x
Dividend Yield
—
Implied Growth (rev. DCF)
5.0%
Rating Score
70/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what DXCM's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. DXCM trades near $69.07, above its 50-day average ($66.47) and 200-day average ($67.53). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 47 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. DXCM's is $2.82 (~4.1% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month DXCM found buyers near $66.30 (support) and sellers near $78.91 (resistance); its 52-week range is $54.11–$89.98. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.7× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Dexcom (DXCM) is a large-cap company in the Health Care Equipment industry, part of the Health Care sector of the S&P 500, with a market value around $27.96B.
In its latest reported year it generated about $4.66B in revenue and $836.30M in net profit.
Our model rates DXCM Favorable (70/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
17.5%
Revenue moved from $2.45B in 2021 to $4.66B in 2025, a 17.5% compound annual growth rate. The most recent year grew a strong 16.1% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
60.1%
Operating Margin
19.6%
Net Margin
17.9%
ROE
33.8%
Dexcom keeps about 19.3% of each sales dollar as net profit, with a 60.1% gross margin and 19.6% operating margin. Return on equity is 33.8% and return on invested capital about 24.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$2.90M
Net Debt
-$1.12B
Net cash position
Net Debt / EBITDA
-1.22x
Debt / Equity
0.47x
Leverage: debt-to-equity is 0.5x, and operating profit covers interest about 44.9x, with a current ratio of 1.9x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $2.90M of total debt against $1.12B of cash.
Operating CF
$1.44B
Free Cash Flow
$1.08B
FCF Margin
23.1%
In the latest year Dexcom produced about $1.44B of operating cash flow and $1.08B of free cash flow after capital spending. That is a free-cash-flow yield of about 1.8% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
30.34x
P/S
6.11x
P/B
9.34x
EV / EBITDA
23.3x
DXCM trades at 30.3x trailing earnings (about 21.7x on estimated forward earnings), 6.1x sales, and 9.3x book value. Reverse-engineering today's price implies the market expects roughly 5.0% long-term free-cash-flow growth. That is a premium multiple that needs growth to justify it.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How DXCM stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), DXCM ranks #5 of 59 by our overall rating. It trades at a premium versus the sector on earnings (30.3x P/E vs. 25.4x median) with a higher return on equity (33.8% vs. 14.9%) and faster revenue growth (16.1% vs. 7.9%).
P/E vs sector
30.3x
median 25.4x
ROE vs sector
33.8%
median 14.9%
Growth vs sector
16.1%
median 7.9%
Sector rank
#5
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$82.22 – $137.03
vs. $69.07 today · expected CAGR 4% – 15%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $5.41B | $6.27B | $7.28B | $8.44B | $9.79B |
| Net income | $973.43M | $1.13B | $1.31B | $1.52B | $1.76B |
| EPS | $2.52 | $2.93 | $3.39 | $3.94 | $4.57 |
| Share price (low) | $45.41 | $52.67 | $61.10 | $70.88 | $82.22 |
| Share price (high) | $75.68 | $87.79 | $101.83 | $118.13 | $137.03 |
| CAGR (low–high) | -34% / 10% | -13% / 13% | -4% / 14% | 1% / 14% | 4% / 15% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for DXCM:
- Revenue is growing 16.1% a year, a sign of real demand.
- High net margins (19.3%) point to pricing power or efficiency.
- Strong return on equity (33.8%) shows capital is put to work well.
- A conservative balance sheet (debt/equity 0.5x) lowers risk.
- Our model's overall read is Favorable (70/100).
The case against DXCM:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Valuation risk — at 30.3x earnings, disappointing results could compress the multiple.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Dexcom is a large-cap health care business still growing nicely, with solid profitability, and a sound balance sheet. It trades at 30.3x earnings, which our model scores Favorable (70/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.